Keros appoints Anne Prener to Board of Directors, effective July 1, 2026

Keros Therapeutics, Inc.

Anne Prener, M.D., Ph.D., appointed as Class III director with term expiring at 2029 annual meeting.
Initial equity grants: $150K option and $150K RSU, each vesting quarterly over three years.
Annual compensation: $75K option, $75K RSU, and $41,500 cash retainer for board service.
Dr. Prener brings clinical development leadership; formerly CEO of Imbria, Freeline, Gyroscope, and exec at Baxalta and Novo Nordisk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.